Detail Information of Exogenous Modulation

General Information of Drug Transporter (DT)
DT ID	DTD0004 Transporter Info
Gene Name	ABCG2
Transporter Name	Breast cancer resistance protein
Gene ID	9429
UniProt ID	Q9UNQ0

Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM)
Approved Drug
Estradiol	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Estradiol inhibits the transportation of Topotecan by ABCG2			[5]
Affected Drug/Substrate	Topotecan	Modulation Type	Inhibition
Cell System	Myelogenous leukemia cell line (K562)-BCRP
DT Modulation 2	Estradiol induces the activity of ABCG2			[10] , [11] , [12]
Imatinib	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Imatinib induces the activity of ABCG2			[8] , [9]
DT Modulation 2	Imatinib inhibits the activity of ABCG2			[8] , [9]
Cyclosporine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Cyclosporine inhibits the transportation of ATPase by ABCG2 (Ki = 0.5 microM)			[13]
Affected Drug/Substrate	ATPase	Modulation Type	Inhibition
Cell System	Spodoptera frugiperda (Sf9) cells-BCRP
DT Modulation 2	Cyclosporine inhibits the activity of ABCG2			[28]
Sulfasalazine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Sulfasalazine inhibits the transportation of Estrone sulfate by ABCG2 (IC50 = 0.73 microM)			[14]
Affected Drug/Substrate	Estrone sulfate	Modulation Type	Inhibition
Cell System	Oocytes-BCRP
DT Modulation 2	Sulfasalazine inhibits the activity of ABCG2			[25]
Gefitinib	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Gefitinib inhibits the transportation of Hoechst 33342 by ABCG2 (IC50 = 0.4 microM)			[15]
Affected Drug/Substrate	Hoechst 33342	Modulation Type	Inhibition
Cell System	Spodoptera frugiperda (Sf9) cells-BCRP
DT Modulation 2	Gefitinib inhibits the activity of ABCG2			[27]
Omeprazole	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Omeprazole inhibits the transportation of Methotrexate by ABCG2 (IC50 = 10-50 microM)			[16]
Affected Drug/Substrate	Methotrexate	Modulation Type	Inhibition
Cell System	Spodoptera frugiperda (Sf9) cells-BCRP
DT Modulation 2	Omeprazole inhibits the activity of ABCG2			[20]
Pantoprazole	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Pantoprazole inhibits the transportation of Methotrexate by ABCG2 (IC50 = 10 microM)			[16]
Affected Drug/Substrate	Methotrexate	Modulation Type	Inhibition
Cell System	Spodoptera frugiperda (Sf9) cells-BCRP
DT Modulation 2	Pantoprazole inhibits the activity of ABCG2			[16] , [20]
Lopinavir	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Lopinavir inhibits the transportation of Pheophorbide A by ABCG2 (IC50 = 7.66 microM)			[17]
Affected Drug/Substrate	Pheophorbide A	Modulation Type	Inhibition
Cell System	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
DT Modulation 2	Lopinavir inhibits the activity of ABCG2			[17]
Nelfinavir	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Nelfinavir inhibits the transportation of Pheophorbide A by ABCG2 (IC50 = 13.5 microM)			[17]
Affected Drug/Substrate	Pheophorbide A	Modulation Type	Inhibition
Cell System	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
DT Modulation 2	Nelfinavir inhibits the activity of ABCG2			[26]
Hesperetin	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Hesperetin inhibits the transportation of mitoxantrone by ABCG2			[18]
Affected Drug/Substrate	mitoxantrone	Modulation Type	Inhibition
Cell System	Human breast adenocarcinoma cell line (MCF-7)-BCRP
DT Modulation 2	Hesperetin inhibits the transportation of SN-38 by ABCG2			[19]
Affected Drug/Substrate	SN-38	Modulation Type	Inhibition
Cell System	Myelogenous leukemia cell line (K562)-BCRP
Etravirine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Etravirine inhibits the activity of ABCG2			[21] , [22]
Progesterone	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Progesterone induces the activity of ABCG2			[23] , [24]
DT Modulation 2	Progesterone inhibits the activity of ABCG2			[24]
Itraconazole	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Itraconazole inhibits the activity of ABCG2			[29] , [30]
Ketoconazole	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Ketoconazole inhibits the activity of ABCG2			[30]
Daunorubicin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Daunorubicin inhibits the transportation of Estrone sulfate by ABCG2 (IC50 = 59 microM)			[31]
Affected Drug/Substrate	Estrone sulfate	Modulation Type	Inhibition
Cell System	Mouse lymphoma (P388) cells-BCRP
Atorvastatin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Atorvastatin inhibits the transportation of Estrone sulfate by ABCG2 (Ki = 14.3 microM)			[32]
Affected Drug/Substrate	Estrone sulfate	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-BCRP
Cerivastatin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Cerivastatin inhibits the transportation of Estrone sulfate by ABCG2 (Ki = 18.1 microM)			[32]
Affected Drug/Substrate	Estrone sulfate	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-BCRP
Fluvastatin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Fluvastatin inhibits the transportation of Estrone sulfate by ABCG2 (Ki = 5.43 microM)			[32]
Affected Drug/Substrate	Estrone sulfate	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-BCRP
Pitavastatin calcium	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Pitavastatin calcium inhibits the transportation of Estrone sulfate by ABCG2 (Ki = 2.92 microM)			[32]
Affected Drug/Substrate	Estrone sulfate	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-BCRP
Rosuvastatin Calcium	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Rosuvastatin inhibits the transportation of Estrone sulfate by ABCG2 (Ki = 15.4 microM)			[32]
Affected Drug/Substrate	Estrone sulfate	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-BCRP
Simvastatin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Simvastatin inhibits the transportation of Estrone sulfate by ABCG2 (Ki = 18 microM)			[32]
Affected Drug/Substrate	Estrone sulfate	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-BCRP
Erlotinib	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Erlotinib inhibits the transportation of Estrone sulfate by ABCG2 (IC50 = 0.13 microM; Ki = 0.15 microM)			[33]
Affected Drug/Substrate	Estrone sulfate	Modulation Type	Inhibition
Cell System	Myelogenous leukemia cell line (K562)-BCRP
Atovaquone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Atovaquone inhibits the transportation of Estrone sulphate by ABCG2 (IC50 = 0.23 microM)			[34]
Affected Drug/Substrate	Estrone sulphate	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-BCRP
Anidulafungin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Anidulafungin inhibits the transportation of Fluorescent protein by ABCG2 (IC50 = 7 microM)			[35]
Affected Drug/Substrate	Fluorescent protein	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-BCRP
Nilotinib	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Nilotinib inhibits the transportation of Methotrexate by ABCG2 (Ki = 0.69 microM)			[38]
Affected Drug/Substrate	Methotrexate	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-BCRP
Abacavir	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Abacavir inhibits the transportation of Pheophorbide A by ABCG2 (IC50 = 385 microM)			[17]
Affected Drug/Substrate	Pheophorbide A	Modulation Type	Inhibition
Cell System	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
Amprenavir	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Amprenavir inhibits the transportation of Pheophorbide A by ABCG2 (IC50 = 181 microM)			[17]
Affected Drug/Substrate	Pheophorbide A	Modulation Type	Inhibition
Cell System	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
Atazanavir	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Atazanavir inhibits the transportation of Pheophorbide A by ABCG2 (IC50 = 69.1 microM)			[17]
Affected Drug/Substrate	Pheophorbide A	Modulation Type	Inhibition
Cell System	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
Delavirdine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Delavirdine inhibits the transportation of Pheophorbide A by ABCG2 (IC50 = 18.7 microM)			[17]
Affected Drug/Substrate	Pheophorbide A	Modulation Type	Inhibition
Cell System	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
Efavirenz	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Efavirenz inhibits the transportation of Pheophorbide A by ABCG2 (IC50 = 20.6 microM)			[17]
Affected Drug/Substrate	Pheophorbide A	Modulation Type	Inhibition
Cell System	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
Saquinavir	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Saquinavir inhibits the transportation of Pheophorbide A by ABCG2 (IC50 = 27.4 microM)			[17]
Affected Drug/Substrate	Pheophorbide A	Modulation Type	Inhibition
Cell System	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
Permethrin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Permethrin inhibits the transportation of Sulfasalazine by ABCG2 (IC50 = 7 microM)			[40]
Affected Drug/Substrate	Sulfasalazine	Modulation Type	Inhibition
Cell System	Spodoptera frugiperda (Sf9) cells-BCRP
Dolutegravir	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Dolutegravir inhibits the transportation of Cimetidine by ABCG2			[44]
Affected Drug/Substrate	Cimetidine	Modulation Type	Inhibition
Cell System	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
Linagliptin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Linagliptin inhibits the transportation of Estrone sulfate by ABCG2			[45]
Affected Drug/Substrate	Estrone sulfate	Modulation Type	Inhibition
Cell System	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
Prazosin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Prazosin inhibits the transportation of Estrone sulfate by ABCG2			[45]
Affected Drug/Substrate	Estrone sulfate	Modulation Type	Inhibition
Cell System	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
Quercetin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Quercetin inhibits the transportation of Mitoxantrone by ABCG2			[18]
Affected Drug/Substrate	Mitoxantrone	Modulation Type	Inhibition
Cell System	Human breast adenocarcinoma cell line (MCF-7)-BCRP
Simeprevir	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Simeprevir inhibits the transportation of Digoxin by ABCG2			[48]
Affected Drug/Substrate	Digoxin	Modulation Type	Inhibition
Calcitriol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Calcitriol inhibits the activity of ABCG2			[50]
Cell System	Human embryonic kidney 293 cells (HEK293)-BCRP
Decitabine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Decitabine inhibits DNA methyltransferase, which then enhances Novobiocin's transportation via downregulating the hypermethylation in ABCG2's promoter			[53]
Affected Drug/Substrate	Novobiocin	Modulation Type	Inducer
Cell System	Human small cell lung cancer cells (PC-6)
Carbamazepine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Carbamazepine increases the expression of ABCG2			[54]
Regulation Mechanism	via enhancement of Nuclear receptor subfamily 1 group I member 2 (NR1I2)			Transcription Factor Info
Cell System	Human liver samples
Rifampin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Rifampin increases the expression of ABCG2			[55]
Regulation Mechanism	via enhancement of Nuclear receptor subfamily 1 group I member 2 (NR1I2)			Transcription Factor Info
Cell System	Human hepatocytes
Cisplatin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Cisplatin increases the expression of ABCG2			[56]
Regulation Mechanism	via enhancement of Bile acid receptor (NR1H4)			Transcription Factor Info
Cell System	human colorectal adenocarcinoma cells (LS174T)
Hydrogen Peroxide	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Hydrogen Peroxide increases the expression of ABCG2			[57]
Regulation Mechanism	via enhancement of Endothelial PAS domain-containing protein 1 (EPAS1)			Transcription Factor Info
Cell System	Human cardiac side population cells
Phenobarbital	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Phenobarbital increases the expression of ABCG2			[58]
Regulation Mechanism	via enhancement of Nuclear receptor subfamily 1 group I member 3 (NR1I3)			Transcription Factor Info
Cell System	Human hepatocytes
Arsenic Trioxide	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Arsenic Trioxide increases the expression of ABCG2			[59]
Regulation Mechanism	via enhancement of Nuclear factor NF-kappa-B p105 subunit (NFKB1)			Transcription Factor Info
Cell System	Human lung adenocarcinoma cells (A549)
Troglitazone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Troglitazone increases the expression of ABCG2			[60]
Regulation Mechanism	via enhancement of Peroxisome proliferator-activated receptor gamma (PPARG)			Transcription Factor Info
Cell System	Human colon adenocarcinoma cells (Caco-2)
Digoxin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Digoxin inhibits the activity of ABCG2			[61]
Imatinib Mesylate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Imatinib Mesylate increases the expression of ABCG2			[9]
Mometasone Furoate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Mometasone Furoate increases the activity of ABCG2			[62]
Estrone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Estrone increases the expression of ABCG2			[12]
Celecoxib	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Celecoxib inhibits the expression of ABCG2			[64]
Zoledronic Acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Zoledronic Acid increases the expression of ABCG2			[65]
Menadione	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Menadione affects the expression of ABCG2			[66]
Testosterone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Testosterone inhibits the activity of ABCG2			[67]
Zidovudine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Zidovudine increases the expression of ABCG2			[68]
Lindane	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Lindane increases the expression of ABCG2			[37]
Ciprofloxacin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Ciprofloxacin increases the expression of ABCG2			[69]
Pravastatin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Pravastatin increases the activity of ABCG2			[70]
Chloroquine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Chloroquine inhibits the expression of ABCG2			[71]
Abemaciclib	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Abemaciclib inhibits the activity of ABCG2			[72]
Crizotinib	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Crizotinib inhibits the activity of ABCG2			[73]
Urethane	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Urethane inhibits the expression of ABCG2			[74]
Methoxsalen	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Methoxsalen inhibits the activity of ABCG2			[75]
Tamoxifen	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Tamoxifen increases the expression of ABCG2			[76]
Dabrafenib	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Dabrafenib increases the expression of ABCG2			[78]
Doxorubicin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Doxorubicin increases the expression of ABCG2			[79]
Tretinoin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Tretinoin increases the expression of ABCG2			[80]
Acetaminophen	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Acetaminophen inhibits the expression of ABCG2			[81]
Valproic Acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Valproic Acid increases the expression of ABCG2			[82]
Dacomitinib	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Dacomitinib inhibits the activity of ABCG2			[83]
Leflunomide	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Leflunomide inhibits the activity of ABCG2			[84]
Doxycycline	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Doxycycline induces the activity of ABCG2			[85]
Mitoxantrone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Mitoxantrone inhibits the activity of ABCG2			[18] , [86]
Telaprevir	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Telaprevir induces the activity of ABCG2			[87]
Osimertinib	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Osimertinib inhibits the activity of ABCG2			[88]
Methotrexate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Methotrexate inhibits the activity of ABCG2			[42]
Folic Acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Folic acid induces the activity of ABCG2			[89] , [90]
Rosiglitazone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Rosiglitazone induces the activity of ABCG2			[8] , [91] , [92]
Dexamethasone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Dexamethasone induces the activity of ABCG2			[93]
Topotecan	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Topotecan induces the activity of ABCG2			[94] , [95]
Nicardipine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Nicardipine inhibits the activity of ABCG2			[96] , [97]
Sirolimus	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Sirolimus inhibits the activity of ABCG2			[98]
Tacrolimus	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Tacrolimus inhibits the activity of ABCG2			[98]
Oxycodone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Oxycodone induces the activity of ABCG2			[99]
Ritonavir	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Ritonavir inhibits the activity of ABCG2			[100]
Dipyridamole	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Dipyridamole inhibits the activity of ABCG2			[101] , [102]
Propafenone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Propafenone inhibits the activity of ABCG2			[103]
Reserpine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Reserpine inhibits the activity of ABCG2			[104] , [105] , [106]
Toremifene	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Toremifene inhibits the activity of ABCG2			[107]
Plicamycin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Plicamycin inhibits the activity of ABCG2			[108]
Insulin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Insulin induces the activity of ABCG2			[109]
Nimodipine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Nimodipine inhibits the activity of ABCG2			[110]
Glecaprevir	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Glecaprevir inhibits the activity of ABCG2			[111]
Tolcapone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Tolcapone inhibits the activity of ABCG2			[112]
Selexipag	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Selexipag inhibits the activity of ABCG2			[113]
Eetuximab	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Eetuximab inhibits the activity of ABCG2			[114]
Oxytetracycline	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Oxytetracycline induces the activity of ABCG2			[115]
Febuxostat	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Febuxostat inhibits the activity of ABCG2			[116]
Micafungin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Micafungin inhibits the activity of ABCG2			[35]
Clofibrate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Clofibrate induces the activity of ABCG2			[117]
Venlafaxine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Venlafaxine induces the activity of ABCG2			[118]
Paclitaxel	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Paclitaxel increases the expression of ABCG2			[119]
Regulation Mechanism	via enhancement of Signal transducer and activator of transcription 3 (STAT3)			Transcription Factor Info
Affected Drug/Substrate	Doxorubicin	Modulation Type	Inducer
Cell System	Human doxorubicin-resistant epithelial ovarian cancer cells (A2780-R)
Drug Marketed but not Approved by US FDA
Catechin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Catechin inhibits the expression of ABCG2			[63]
Estriol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Estriol increases the expression of ABCG2			[11]
Drug in Phase 4 Trial
Glafenine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Glafenine inhibits the activity of ABCG2			[155]
Drug in Phase 2/3 Trial
Butyric Acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Butyric Acid increases the expression of ABCG2			[77]
Drug in Phase 3 Trial
Curcumin	4 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Curcumin inhibits the transportation of Mitoxantrone by ABCG2			[1]
Affected Drug/Substrate	Mitoxantrone	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-BCRP
DT Modulation 2	Curcumin inhibits the transportation of Pheophorbide by ABCG2			[1]
Affected Drug/Substrate	Pheophorbide	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-BCRP
DT Modulation 3	Curcumin inhibits the transportation of Resveratrol-3-O-glucuronide by ABCG2			[2]
Affected Drug/Substrate	Resveratrol-3-O-glucuronide	Modulation Type	Inhibition
Cell System	Model organism in vivo (mouse)
DT Modulation 4	Curcumin inhibits the transportation of Sulfasalazine by ABCG2			[3]
Affected Drug/Substrate	Sulfasalazine	Modulation Type	Inhibition
Cell System	Model organism in vivo (mouse)
Corticosterone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Corticosterone inhibits the activity of ABCG2			[61]
Resveratrol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Resveratrol inhibits the expression of ABCG2			[134]
Triclosan	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Triclosan increases the expression of ABCG2			[145]
Drug in Phase 2 Trial
SN-38	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	SN-38 inhibits the transportation of Estrone sulfate by ABCG2 (IC50 = 1.6 microM)			[31]
Affected Drug/Substrate	Estrone sulfate	Modulation Type	Inhibition
Cell System	Mouse lymphoma (P388) cells-BCRP
Genistein	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Genistein inhibits the transportation of Mitoxantrone by ABCG2			[18]
Affected Drug/Substrate	Mitoxantrone	Modulation Type	Inhibition
Cell System	Human breast adenocarcinoma cell line (MCF-7)-BCRP
Bisphenol A	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Bisphenol A increases the expression of ABCG2			[122]
Regulation Mechanism	via enhancement of Nuclear factor erythroid 2-related factor 2 (NFE2L2)			Transcription Factor Info
Cell System	Human fetal liver samples
Sulindac sulfide	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Sulindac sulfide increases the expression of ABCG2			[125]
Colforsin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Colforsin increases the expression of ABCG2			[130]
Ethanol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Ethanol increases the expression of ABCG2			[151]
Drug in Phase 1 Trial
Naringenin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Naringenin inhibits the transportation of Mitoxantrone by ABCG2			[18]
Affected Drug/Substrate	Mitoxantrone	Modulation Type	Inhibition
Cell System	Human breast adenocarcinoma cell line (MCF-7)-BCRP
Oxfendazole	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Oxfendazole inhibits the activity of ABCG2			[124]
Sodium arsenite	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Sodium arsenite inhibits the expression of ABCG2			[131]
HSDB-3466	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	HSDB-3466 inhibits the activity of ABCG2			[75]
TAK-875	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	TAK-875 inhibits the activity of ABCG2			[148]
Q-100154	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Q-100154 inhibits the expression of ABCG2			[149]
Trichostatin A	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Trichostatin A increases the expression of ABCG2			[140]
Drug in Preclinical Test
Oleic Acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Oleic Acid increases the expression of ABCG2			[135]
(+)-JQ1	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	(+)-JQ1 inhibits the expression of ABCG2			[141]
Anandamide	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Anandamide inhibits the expression of ABCG2			[147]
Discontinued Drug
Elacridar	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Elacridar inhibits the transportation of Mitoxantrone by ABCG2 (IC50 = 0.31 microM)			[4]
Affected Drug/Substrate	Mitoxantrone	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-BCRP
DT Modulation 2	Elacridar inhibits the transportation of Estrone sulfate by ABCG2			[6]
Affected Drug/Substrate	Estrone sulfate	Modulation Type	Inhibition
Cell System	Human enterocyte-like 2 cell (Caco-2)-BCRP
DT Modulation 3	Elacridar inhibits the transportation of Mitoxantrone by ABCG2			[7]
Affected Drug/Substrate	Mitoxantrone	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-BCRP
Tariquidar	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Tariquidar inhibits the transportation of Calcein AM by ABCG2			[49]
Affected Drug/Substrate	Calcein AM	Modulation Type	Inhibition
Investigative Drug
Coumestrol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Coumestrol inhibits the transportation of Methotrexate by ABCG2 (IC50 = 0.063 microM)			[42]
Affected Drug/Substrate	Methotrexate	Modulation Type	Inhibition
Daidzein	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Daidzein inhibits the transportation of Mitoxantrone by ABCG2			[18]
Affected Drug/Substrate	Mitoxantrone	Modulation Type	Inhibition
Cell System	Human breast adenocarcinoma cell line (MCF-7)-BCRP
Kaempferol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Kaempferol inhibits the transportation of Mitoxantrone by ABCG2			[18]
Affected Drug/Substrate	Mitoxantrone	Modulation Type	Inhibition
Cell System	Human breast adenocarcinoma cell line (MCF-7)-BCRP
Morin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Morin inhibits the transportation of Mitoxantrone by ABCG2			[18]
Affected Drug/Substrate	Mitoxantrone	Modulation Type	Inhibition
Cell System	Human breast adenocarcinoma cell line (MCF-7)-BCRP
GW9662	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	GW9662 inhibits the expression of ABCG2			[60]
Regulation Mechanism	via the inhibition of Peroxisome proliferator-activated receptor gamma (PPARG)			Transcription Factor Info
Cell System	Sprague-Dawley rats
Desisobutyryl-ciclesonide	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Desisobutyryl-ciclesonide increases the activity of ABCG2			[62]
Beta-naphthoflavone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Beta-naphthoflavone increases the expression of ABCG2			[132]
Phenylmercuric Acetate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Phenylmercuric Acetate increases the expression of ABCG2			[140]
N-nonylphenol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	N-nonylphenol inhibits the expression of ABCG2			[142]
Chloropyrifos oxon	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Chloropyrifos oxon increases the expression of ABCG2			[152]
Rutin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Rutin inhibits the activity of ABCG2			[42]
Patented Pharmaceutical Agent
AM-251	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	AM-251 increases the expression of ABCG2			[143]
GW-4064	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	GW-4064 inhibits the expression of ABCG2			[151]
Drug Withdrawn
Nimesulide	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Nimesulide inhibits the expression of ABCG2			[127]
Natural Product
Pyrethroids	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Pyrethroids inhibits the transportation of Fmitremorgin C by ABCG2 (IC50 = 42.5 microM)			[36]
Affected Drug/Substrate	Fmitremorgin C	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-BCRP
Tetramethrin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Tetramethrin inhibits the transportation of Fmitremorgin C by ABCG2 (IC50 = 72.5 microM)			[36]
Affected Drug/Substrate	Fmitremorgin C	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-BCRP
Chlordecone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Chlordecone inhibits the transportation of Hoechst 33342 by ABCG2 (IC50 = 90.4 microM)			[37]
Affected Drug/Substrate	Hoechst 33342	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-BCRP
Endosulfan	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Endosulfan inhibits the transportation of Hoechst 33342 by ABCG2 (IC50 = 24.8 microM)			[37]
Affected Drug/Substrate	Hoechst 33342	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-BCRP
Isoflavones	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Isoflavones inhibits the transportation of Mitoxantrone by ABCG2 in a non-competitive manner (IC50 = 8.8 microM)			[39]
Affected Drug/Substrate	Mitoxantrone	Modulation Type	Inhibition
Cell System	Human breast adenocarcinoma cell line (MCF-7)-BCRP
Resmethrin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Resmethrin inhibits the transportation of Sulfasalazine by ABCG2 (IC50 = 5.6 microM)			[40]
Affected Drug/Substrate	Sulfasalazine	Modulation Type	Inhibition
Cell System	Spodoptera frugiperda (Sf9) cells-BCRP
Azoxystrobin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Azoxystrobin inhibits the transportation of WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) by ABCG2 (IC50 = 1860 microM)			[41]
Affected Drug/Substrate	WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate)	Modulation Type	Inhibition
Cell System	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
Chlormequate chloride	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Chlormequate chloride inhibits the transportation of WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) by ABCG2 (IC50 = 1260 microM)			[41]
Affected Drug/Substrate	WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate)	Modulation Type	Inhibition
Cell System	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
Chlorpyrifos	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Chlorpyrifos inhibits the transportation of WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) by ABCG2 (IC50 = 285 microM)			[41]
Affected Drug/Substrate	WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate)	Modulation Type	Inhibition
Cell System	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
Chlorpyrifos-methyl	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Chlorpyrifos-methyl inhibits the transportation of WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) by ABCG2 (IC50 = 31 microM)			[41]
Affected Drug/Substrate	WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate)	Modulation Type	Inhibition
Cell System	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
Diflufenican	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Diflufenican inhibits the transportation of WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) by ABCG2 (IC50 = 13 microM)			[41]
Affected Drug/Substrate	WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate)	Modulation Type	Inhibition
Cell System	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
Dimethoate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Dimethoate inhibits the transportation of WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) by ABCG2 (IC50 = 22 microM)			[41]
Affected Drug/Substrate	WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate)	Modulation Type	Inhibition
Cell System	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
Dimethomorph	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Dimethomorph inhibits the transportation of WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) by ABCG2 (IC50 = 26 microM)			[41]
Affected Drug/Substrate	WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate)	Modulation Type	Inhibition
Cell System	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
Dithianon	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Dithianon inhibits the transportation of WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) by ABCG2 (IC50 = 202 microM)			[41]
Affected Drug/Substrate	WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate)	Modulation Type	Inhibition
Cell System	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
Epoxiconazole	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Epoxiconazole inhibits the transportation of WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) by ABCG2 (IC50 = 455 microM)			[41]
Affected Drug/Substrate	WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate)	Modulation Type	Inhibition
Cell System	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
Glyphosate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Glyphosate inhibits the transportation of WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) by ABCG2 (IC50 = 148 microM)			[41]
Affected Drug/Substrate	WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate)	Modulation Type	Inhibition
Cell System	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
Enilconazole	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Imazalil inhibits the transportation of WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) by ABCG2 (IC50 = 109 microM)			[41]
Affected Drug/Substrate	WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate)	Modulation Type	Inhibition
Cell System	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
Ioxynil	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Ioxynil inhibits the transportation of WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) by ABCG2 (IC50 = 540 microM)			[41]
Affected Drug/Substrate	WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate)	Modulation Type	Inhibition
Cell System	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
Methiocarb	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Methiocarb inhibits the transportation of WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) by ABCG2 (IC50 = 440 microM)			[41]
Affected Drug/Substrate	WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate)	Modulation Type	Inhibition
Cell System	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
Rimsulfuron	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Rimsulfuron inhibits the transportation of WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) by ABCG2 (IC50 = 12 microM)			[41]
Affected Drug/Substrate	WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate)	Modulation Type	Inhibition
Cell System	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
Thiacloprid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Thiacloprid inhibits the transportation of WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) by ABCG2 (IC50 = 396 microM)			[41]
Affected Drug/Substrate	WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate)	Modulation Type	Inhibition
Cell System	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
Tolclofos-methyl	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Tolclofos-methyl inhibits the transportation of WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) by ABCG2 (IC50 = 17 microM)			[41]
Affected Drug/Substrate	WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate)	Modulation Type	Inhibition
Cell System	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
Berry anthocyanins	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Berry anthocyanins inhibits the activity of ABCG2 (IC50 = 7.8 microM)			[43]
Cell System	Human breast adenocarcinoma cell line (MCF-7)-BCRP
Cigarette smoke condensate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Cigarette smoke condensate induces the transportation of Hoechst 33342 by ABCG2			[46]
Affected Drug/Substrate	Hoechst 33342	Modulation Type	Inducer
Cell System	Human hepatoma HepaRG cells-BCRP
Epigallocatechin gallate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Epigallocatechin gallate inhibits the transportation of Mitoxantrone by ABCG2			[18]
Affected Drug/Substrate	Mitoxantrone	Modulation Type	Inhibition
Cell System	Human breast adenocarcinoma cell line (MCF-7)-BCRP
Luteolin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Luteolin inhibits the transportation of Mitoxantrone by ABCG2			[18]
Affected Drug/Substrate	Mitoxantrone	Modulation Type	Inhibition
Cell System	Human breast adenocarcinoma cell line (MCF-7)-BCRP
Cinnamic acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Cinnamic acid inhibits the transportation of Rosuvastatin by ABCG2 in a competitive manner			[47]
Affected Drug/Substrate	Rosuvastatin	Modulation Type	Inhibition
Cell System	Madin darby canine kidney strain cell line (MDCK)-BCRP
Gallic Acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Gallic acid inhibits the transportation of Rosuvastatin by ABCG2 in a competitive manner			[47]
Affected Drug/Substrate	Rosuvastatin	Modulation Type	Inhibition
Cell System	Madin darby canine kidney strain cell line (MDCK)-BCRP
Piperine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Piperine inhibits the transportation of Rosuvastatin by ABCG2 in a competitive manner			[47]
Affected Drug/Substrate	Rosuvastatin	Modulation Type	Inhibition
Cell System	Madin darby canine kidney strain cell line (MDCK)-BCRP
Tripterine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Celastrol inhibits the activity of ABCG2			[51]
Cell System	Human embryonic kidney 293 cells (HEK293)-BSEP
Chrysoeriol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Chrysoeriol inhibits the activity of ABCG2			[51]
Cell System	Human embryonic kidney 293 cells (HEK293)-BSEP
Ellagic acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Ellagic acid inhibits the activity of ABCG2			[51]
Cell System	Human embryonic kidney 293 cells (HEK293)-BSEP
Laricitrin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Laricitrin inhibits the activity of ABCG2			[51]
Cell System	Human embryonic kidney 293 cells (HEK293)-BSEP
Limonin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Limonin inhibits the activity of ABCG2			[51]
Cell System	Human embryonic kidney 293 cells (HEK293)-BSEP
Oleanolic acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Oleanolic acid inhibits the activity of ABCG2			[51]
Cell System	Human embryonic kidney 293 cells (HEK293)-BSEP
Propyl gallate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Propyl gallate inhibits the activity of ABCG2			[51]
Cell System	Human embryonic kidney 293 cells (HEK293)-BSEP
Sinapic acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Sinapic acid inhibits the activity of ABCG2			[51]
Cell System	Human embryonic kidney 293 cells (HEK293)-BSEP
Tamarixetin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Tamarixetin inhibits the activity of ABCG2			[51]
Cell System	Human embryonic kidney 293 cells (HEK293)-BSEP
Tricetin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Tricetin inhibits the activity of ABCG2			[51]
Cell System	Human embryonic kidney 293 cells (HEK293)-BSEP
Tricetin 3',4',5'-trimethylether	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Tricetin 3',4',5'-trimethylether inhibits the activity of ABCG2			[51]
Cell System	Human embryonic kidney 293 cells (HEK293)-BSEP
Ursolic acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Ursolic acid inhibits the activity of ABCG2			[51]
Cell System	Human embryonic kidney 293 cells (HEK293)-BSEP
Black cohosh extract (1mg/ml)	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Black cohosh extract (1mg/ml) inhibits the activity of ABCG2			[42]
Cell System	Mammalian cells expressing human wild-type BCRP
Gymnema sylvestre extract (1mg/ml)	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Gymnema sylvestre extract (1mg/ml) inhibits the activity of ABCG2			[42]
Cell System	Mammalian cells expressing human wild-type BCRP
Passion flower extract (1mg/ml)	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Passion flower extract (1mg/ml) inhibits the activity of ABCG2			[42]
Cell System	Mammalian cells expressing human wild-type BCRP
Rutin extract (1mg/ml)	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Rutin extract (1mg/ml) inhibits the activity of ABCG2			[42]
Cell System	Mammalian cells expressing human wild-type BCRP
Soybean extract (1mg/ml)	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Soybean extract (1mg/ml) inhibits the activity of ABCG2 (IC50 = 16.5 microM)			[42]
Cell System	Mammalian cells expressing human wild-type BCRP
Tetrahydrocurcumin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Tetrahydrocurcumin inhibits the activity of ABCG2			[52]
Cell System	Human breast adenocarcinoma cell line (MCF-7)-BCRP
Flavone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Flavone increases the expression of ABCG2			[63]
Regulation Mechanism	via enhancement of Aryl hydrocarbon receptor (AHR)			Transcription Factor Info
Cell System	Human colon adenocarcinoma cells (Caco-2)
Chrysin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Chrysin increases the expression of ABCG2			[63]
Regulation Mechanism	via enhancement of Aryl hydrocarbon receptor (AHR)			Transcription Factor Info
Cell System	Human colon adenocarcinoma cells (Caco-2)
6-bromoindirubin-3'-oxime	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	6-bromoindirubin-3'-oxime increases the expression of ABCG2			[128]
Vitallium	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Vitallium inhibits the expression of ABCG2			[137]
Cholesterol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Cholesterol increases the activity of ABCG2			[70]
Mitragynine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Mitragynine affects the activity of ABCG2			[146]
Indolo(3,2-b)carbazole	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Indolo(3,2-b)carbazole increases the expression of ABCG2			[63]
Particulate Matter	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Particulate Matter increases the expression of ABCG2			[153]
Tobacco Smoke Pollution	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Tobacco Smoke Pollution increases the expression of ABCG2			[154]
Oroxylin A	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Oroxylin A inhibits the activity of ABCG2 (IC50 = 0.477 microM)			[156]
Cell System	Human embryonic kidney 293 cells (HEK293)-ABCG2
Plant Extract
Ginkgo biloba extract	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Ginkgo biloba extract increases the expression of ABCG2			[8]
Regulation Mechanism	via enhancement of Aryl hydrocarbon receptor (AHR)			Transcription Factor Info
Cell System	Human colon adenocarcinoma cells (LS174T)
Environmental toxicant
o,p'-dichlorodiphenyltrichloroethane (DDT)	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	O,p'-DDT inhibits the transportation of Sulfasalazine by ABCG2 (IC50 = 10.4 microM)			[40]
Affected Drug/Substrate	Sulfasalazine	Modulation Type	Inhibition
Cell System	Spodoptera frugiperda (Sf9) cells-BCRP
p,p'-dichlorodiphenyldichloroethane (DDE)	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	p,p'-DDE inhibits the transportation of Sulfasalazine by ABCG2 (IC50 = 4 microM)			[40]
Affected Drug/Substrate	Sulfasalazine	Modulation Type	Inhibition
Cell System	Spodoptera frugiperda (Sf9) cells-BCRP
p,p'-dichlorodiphenyltrichloroethane (DDT)	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	p,p'-DDT inhibits the transportation of Sulfasalazine by ABCG2 (IC50 = 5 microM)			[40]
Affected Drug/Substrate	Sulfasalazine	Modulation Type	Inhibition
Cell System	Spodoptera frugiperda (Sf9) cells-BCRP
p,p'-tetrachlorodiphenylethane (DDD)	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	p,p'-DDD inhibits the transportation of Sulfasalazine by ABCG2 (IC50 = 3 microM)			[40]
Affected Drug/Substrate	Sulfasalazine	Modulation Type	Inhibition
Cell System	Spodoptera frugiperda (Sf9) cells-BCRP
Carbendazim	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Carbendazim inhibits the transportation of WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) by ABCG2 (IC50 = 525 microM)			[41]
Affected Drug/Substrate	WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate)	Modulation Type	Inhibition
Cell System	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
2-tert-butylhydroquinone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	2-tert-butylhydroquinone increases the expression of ABCG2			[120]
Regulation Mechanism	via enhancement of Nuclear factor erythroid 2-related factor 2 (NFE2L2)			Transcription Factor Info
Cell System	Human hepatoblastoma cells (HepG2)
Polychlorinated dibenzodioxin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Polychlorinated dibenzodioxin increases the expression of ABCG2			[123]
Regulation Mechanism	via enhancement of Aryl hydrocarbon receptor (AHR)			Transcription Factor Info
Cell System	Human colon carcinoma cells (HCT 116)
NCX-4040	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	NCX-4040 increases the expression of ABCG2			[133]
Dichlorodiphenyl Dichloroethylene	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Dichlorodiphenyl Dichloroethylene inhibits the activity of ABCG2			[40]
Tetrabromobisphenol A	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Tetrabromobisphenol A inhibits the activity of ABCG2			[138]
Mycotoxins
Aflatoxin B1	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Aflatoxin B1 inhibits the expression of ABCG2			[136]
Acute Toxic Substance
Cadmium	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Cadmium increases the expression of ABCG2			[126]
Mercury	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Mercury increases the expression of ABCG2			[126]
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine inhibits the expression of ABCG2			[129]
Mercuric Chloride	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Mercuric Chloride increases the expression of ABCG2			[139]
Okadaic Acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Okadaic Acid increases the expression of ABCG2			[150]
Carcinogen
Methylcholanthrene	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Methylcholanthrene increases the expression of ABCG2			[121]
Regulation Mechanism	via enhancement of Aryl hydrocarbon receptor (AHR)			Transcription Factor Info
Cell System	Human placental trophoblast cells (TR-S)
Dimethyl nitrosamine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Dimethyl nitrosamine increases the expression of ABCG2			[126]
2-acetylaminofluorene	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	2-acetylaminofluorene increases the activity of ABCG2			[70]
Pesticide/Insecticide
Dieldrin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Dieldrin increases the expression of ABCG2			[37]
Heptachlor	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Heptachlor inhibits the activity of ABCG2			[37]
Health and Environmental Toxicant
Androstenedione	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Androstenedione inhibits the activity of ABCG2			[67]
Perfluorooctane sulfonic acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Perfluorooctane sulfonic acid inhibits the activity of ABCG2			[138]
Chlordan	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Chlordan inhibits the activity of ABCG2			[37]
Azaspiracid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation 1	Azaspiracid increases the expression of ABCG2			[144]

References
1	Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin. Mol Cancer Ther. 2006 Aug;5(8):1995-2006.
2	Curcumin Affects Phase II Disposition of Resveratrol Through Inhibiting Efflux Transporters MRP2 and BCRP. Pharm Res. 2016 Mar;33(3):590-602.
3	Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
4	Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2. Cancer Res. 2005 Jun 1;65(11):4852-60.
5	Estrone and 17beta-estradiol reverse breast cancer resistance protein-mediated multidrug resistance. Jpn J Cancer Res. 2002 Mar;93(3):231-5.
6	Cerebrospinal fluid can be used as a surrogate to assess brain exposures of breast cancer resistance protein and P-glycoprotein substrates. Drug Metab Dispos. 2012 Apr;40(4):779-87.
7	Acridone derivatives: design, synthesis, and inhibition of breast cancer resistance protein ABCG2. Bioorg Med Chem. 2007 Apr 15;15(8):2892-7.
8	A novel xenobiotic responsive element regulated by aryl hydrocarbon receptor is involved in the induction of BCRP/ABCG2 in LS174T cells. Biochem Pharmacol. 2010 Dec 1;80(11):1754-61.
9	Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther. 2005 Jul;4(7):747-52.
10	Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference. Mol Cancer Ther. 2004 Dec;3(12):1577-83.
11	Hormonal regulation of BCRP expression in human placental BeWo cells. Pharm Res. 2008 Feb;25(2):444-52.
12	Effects of sex hormones on regulation of ABCG2 expression in the placental cell line BeWo. J Pharm Pharm Sci. 2006;9(1):133-9.
13	Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun. 2001 Jul 6;285(1):111-7.
14	In vitro risk assessment of AZD9056 perpetrating a transporter-mediated drug-drug interaction with methotrexate. Eur J Pharm Sci. 2011 May 18;43(1-2):41-9.
15	High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol. 2004 Jun;65(6):1485-95.
16	Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res. 2004 Aug 15;64(16):5804-11.
17	Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother. 2007 Feb;59(2):238-45.
18	Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol. 2004 May;65(5):1208-16.
19	Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res. 2004 Jun 15;64(12):4346-52.
20	Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol. 2009 Jan;67(1):44-9.
21	Interaction potential of etravirine with drug transporters assessed in vitro. Antimicrob Agents Chemother. 2011 Mar;55(3):1282-4.
22	Etravirine inhibits ABCG2 drug transporter and affects transplacental passage of tenofovir disoproxil fumarate. Placenta. 2016 Nov;47:124-129.
23	Regulation of BCRP/ABCG2 expression by progesterone and 17beta-estradiol in human placental BeWo cells. Am J Physiol Endocrinol Metab. 2006 May;290(5):E798-807.
24	Dexamethasone down-regulates ABCG2 expression levels in breast cancer cells. Biochem Biophys Res Commun. 2008 Oct 24;375(3):308-14.
25	The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol. 1996 Mar 1;156(5):1937-41.
26	HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2004 Jul;310(1):334-41.
27	Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer Res. 2006 May 1;66(9):4802-7.
28	Effects of breast cancer resistance protein inhibitors and pharmaceutical excipients on decreasing gastrointestinal toxicity of camptothecin analogs. Acta Pharmacol Sin. 2008 Nov;29(11):1391-8.
29	Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP). J Pharm Sci. 2007 Dec;96(12):3226-35.
30	Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters. Drug Metab Dispos. 2016 Mar;44(3):453-9.
31	ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem. 2003 Jun 20;278(25):22644-9.
32	Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol. 2005 Sep;68(3):800-7.
33	Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib. Cancer Sci. 2009 Sep;100(9):1701-7.
34	Atovaquone and quinine anti-malarials inhibit ATP binding cassette transporter activity. Malar J. 2014 Sep 13;13:359.
35	Inhibitory Potential of Antifungal Drugs on ATP-Binding Cassette Transporters P-Glycoprotein, MRP1 to MRP5, BCRP, and BSEP. Antimicrob Agents Chemother. 2016 May 23;60(6):3372-9.
36	Inhibition of Human Drug Transporter Activities by the Pyrethroid Pesticides Allethrin and Tetramethrin. PLoS One. 2017 Jan 18;12(1):e0169480.
37	Regulation of hepatic drug transporter activity and expression by organochlorine pesticides. J Biochem Mol Toxicol. 2014 Mar;28(3):119-28.
38	Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol. 2009 Jul 15;78(2):153-61.
39	Interaction of Isoflavones with the BCRP/ABCG2 Drug Transporter. Curr Drug Metab. 2015;16(2):124-40.
40	Inhibition of human MDR1 and BCRP transporter ATPase activity by organochlorine and pyrethroid insecticides. J Biochem Mol Toxicol. 2013 Feb;27(2):157-64.
41	Assessment of ABCG2-mediated transport of pesticides across the rabbit placenta barrier using a novel MDCKII in vitro model. Toxicol Appl Pharmacol. 2016 Aug 15;305:66-74.
42	Inhibitory effects of herbal extracts on breast cancer resistance protein (BCRP) and structure-inhibitory potency relationship of isoflavonoids. Drug Metab Pharmacokinet. 2010;25(2):170-9.
43	Berry anthocyanins and anthocyanidins exhibit distinct affinities for the efflux transporters BCRP and MDR1. Br J Pharmacol. 2009 Dec;158(8):1942-50.
44	In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos. 2013 Feb;41(2):353-61.
45	Evaluation and prediction of potential drug-drug interactions of linagliptin using in vitro cell culture methods. Drug Metab Dispos. 2013 Jan;41(1):149-58.
46	Alteration of human hepatic drug transporter activity and expression by cigarette smoke condensate. Toxicology. 2016 Jul 1;363-364:58-71.
47	Effects of piperine, cinnamic acid and gallic acid on rosuvastatin pharmacokinetics in rats. Phytother Res. 2013 Oct;27(10):1548-56.
48	Drug-Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir. Clin Pharmacokinet. 2016 Feb;55(2):197-208.
49	New Inhibitors of Breast Cancer Resistance Protein (ABCG2) Containing a 2,4-Disubstituted Pyridopyrimidine Scaffold. J Med Chem. 2018 Apr 26;61(8):3389-3408.
50	Calcitriol and Calcipotriol Modulate Transport Activity of ABC Transporters and Exhibit Selective Cytotoxicity in MRP1-overexpressing Cells. Drug Metab Dispos. 2018 Dec;46(12):1856-1866.
51	Identification of novel dietary phytochemicals inhibiting the efflux transporter breast cancer resistance protein (BCRP/ABCG2). Food Chem. 2013 Jun 15;138(4):2267-74.
52	Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. Mol Cell Biochem. 2007 Feb;296(1-2):85-95.
53	Methylation status of breast cancer resistance protein detected by methylation-specific polymerase chain reaction analysis is correlated inversely with its expression in drug-resistant lung cancer cells. Cancer. 2008 Mar 1;112(5):1122-30.
54	Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. Clin Pharmacol Ther. 2006 Nov;80(5):440-456.
55	Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab Dispos. 2006 Oct;34(10):1756-63.
56	Cisplatin-induced chemoresistance in colon cancer cells involves FXR-dependent and FXR-independent up-regulation of ABC proteins. Mol Pharm. 2012 Sep 4;9(9):2565-76.
57	Hypoxia-inducible factor-2alpha transactivates Abcg2 and promotes cytoprotection in cardiac side population cells. Circ Res. 2008 May 9;102(9):1075-81.; 2008 May 9;102(9):1075-81.
58	Transactivation of ABCG2 through a novel cis-element in the distal promoter by constitutive androstane receptor but not pregnane X receptor in human hepatocytes. Arch Biochem Biophys. 2012 Jan 15;517(2):123-30.
59	Regulation of ABCG2 by nuclear factor kappa B affects the sensitivity of human lung adenocarcinoma A549 cells to arsenic trioxide. Environ Toxicol Pharmacol. 2018 Jan;57:141-150.; 2018 Jan;57:141-150.
60	Short-chain fatty acids exert opposite effects on the expression and function of p-glycoprotein and breast cancer resistance protein in rat intestine. Acta Pharmacol Sin. 2021 Mar;42(3):470-481.; 2021 Mar;42(3):470-481.
61	Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine. J Pharmacol Exp Ther. 2005 Jan;312(1):144-52.
62	Modulation of p-glycoprotein and breast cancer resistance protein by some prescribed corticosteroids. Eur J Pharmacol. 2006 Feb 15;531(1-3):25-33.
63	Phytochemicals induce breast cancer resistance protein in Caco-2 cells and enhance the transport of benzo[a]pyrene-3-sulfate. Toxicol Sci. 2007 Apr;96(2):227-36.
64	Differential effects of selective cyclooxygenase-2 inhibitors in inhibiting proliferation and induction of apoptosis in oral squamous cell carcinoma. Oncol Rep. 2008 Feb;19(2):425-33.
65	In vitro evaluation of zoledronic acid resistance developed in MCF-7 cells. Anticancer Res. 2007 Nov-Dec;27(6B):4031-7.
66	Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203.
67	Localization of breast cancer resistance protein (Bcrp) in endocrine organs and inhibition of its transport activity by steroid hormones. Cell Tissue Res. 2012 Aug;349(2):551-63.
68	Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23.
69	Ciprofloxacin mediates cancer stem cell phenotypes in lung cancer cells through caveolin-1-dependent mechanism. Chem Biol Interact. 2016 Apr 25;250:1-11.
70	Functional characterization of rainbow trout (Oncorhynchus mykiss) Abcg2a (Bcrp) transporter. Comp Biochem Physiol C Toxicol Pharmacol. 2016 Dec;190:15-23.
71	Autophagy inhibition upregulates CD4+ tumor infiltrating lymphocyte expression via miR-155 regulation and TRAIL activation. Mol Oncol. 2016 Dec;10(10):1516-1531.
72	Effect of abemaciclib (LY2835219) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo. Biochem Pharmacol. 2017 Jan 15;124:29-42.
73	Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon. Toxicol Sci. 2017 Jun 1;157(2):500-509.
74	Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
75	ABC-transporter blockage mediated by xanthotoxin and bergapten is the major pathway for chemosensitization of multidrug-resistant cancer cells. Toxicol Appl Pharmacol. 2017 Dec 15;337:22-29.
76	The formation of estrogen-like tamoxifen metabolites and their influence on enzyme activity and gene expression of ADME genes. Arch Toxicol. 2018 Mar;92(3):1099-1112.
77	Butyrate interacts with benzo[a]pyrene to alter expression and activities of xenobiotic metabolizing enzymes involved in metabolism of carcinogens within colon epithelial cell models. Toxicology. 2019 Jan 15;412:1-11.
78	Dabrafenib inhibits ABCG2 and cytochrome P450 isoenzymes; potential implications for combination anticancer therapy. Toxicol Appl Pharmacol. 2022 Jan 1;434:115797.
79	Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance. Neoplasia. 2009 Dec;11(12):1359-70.
80	Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
81	Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
82	Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
83	DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB11963)
84	Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance. Ann Rheum Dis. 2009 Jul;68(7):1201-7.
85	Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
86	Induction of the ABC-transporters Mdr1/P-gp (Abcb1), mrpl (Abcc1), and bcrp (Abcg2) during establishment of multidrug resistance following exposure to mitoxantrone. J Chemother. 2005 Apr;17(2):215-23.
87	Telaprevir is a substrate and moderate inhibitor of P-glycoprotein, a strong inductor of ABCG2, but not an activator of PXR in vitro. Int J Antimicrob Agents. 2014 Feb;43(2):184-8.
88	Osimertinib (AZD9291) Enhanced the Efficacy of Chemotherapeutic Agents in ABCB1- and ABCG2-Overexpressing Cells In Vitro, In Vivo, and Ex Vivo. Mol Cancer Ther. 2016 Aug;15(8):1845-58.
89	Molecular mechanisms of adaptation to folate deficiency. Vitam Horm. 2008;79:99-143.
90	The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Drug Resist Updat. 2006 Aug-Oct;9(4-5):227-46.
91	ATP-binding cassette transporters in human heart failure. Naunyn Schmiedebergs Arch Pharmacol. 2008 May;377(3):231-43.
92	Interaction of thiazolidinediones (glitazones) with the ATP-binding cassette transporters P-glycoprotein and breast cancer resistance protein. Pharmacology. 2009;84(5):264-70.
93	Dexamethasone increases expression and activity of multidrug resistance transporters at the rat blood-brain barrier. Am J Physiol Cell Physiol. 2008 Aug;295(2):C440-50.
94	Progesterone acts via progesterone receptors A and B to regulate breast cancer resistance protein expression. Mol Pharmacol. 2008 Mar;73(3):613-5.
95	ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev. 2007 Mar;26(1):39-57.
96	The role of placental breast cancer resistance protein in the efflux of glyburide across the human placenta. Placenta. 2008 Aug;29(8):743-7.
97	ABCG2 is related with the grade of glioma and resistance to mitoxantone, a chemotherapeutic drug for glioma. J Cancer Res Clin Oncol. 2009 Oct;135(10):1369-76.
98	Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Cancer Chemother Pharmacol. 2006 Sep;58(3):374-83.
99	Regulation of gene expression in brain tissues of rats repeatedly treated by the highly abused opioid agonist, oxycodone: microarray profiling and gene mapping analysis. Drug Metab Dispos. 2010 Jan;38(1):157-67.
100	In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent. Clin Cancer Res. 2005 Dec 1;11(23):8503-11.
101	Disposition of naringenin via glucuronidation pathway is affected by compensating efflux transporters of hydrophilic glucuronides. Mol Pharm. 2009 Nov-Dec;6(6):1703-15.
102	Variable isoflavone content of red clover products affects intestinal disposition of biochanin A, formononetin, genistein, and daidzein. J Altern Complement Med. 2008 Apr;14(3):287-97.
103	Multispecificity of drug transporters: probing inhibitor selectivity for the human drug efflux transporters ABCB1 and ABCG2. ChemMedChem. 2007 Dec;2(12):1783-8.
104	Carboxylesterase-mediated sensitization of human tumor cells to CPT-11 cannot override ABCG2-mediated drug resistance. Mol Pharmacol. 2003 Aug;64(2):279-88.
105	Transport and metabolism of MitoQ10, a mitochondria-targeted antioxidant, in Caco-2 cell monolayers. J Pharm Pharmacol. 2007 Apr;59(4):503-11.
106	The anti-oxidative role of ABCG2 in corneal epithelial cells. Invest Ophthalmol Vis Sci. 2010 Nov;51(11):5617-22.
107	Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells. Breast Cancer Res Treat. 2010 Oct;123(3):679-89.
108	Response of the ABCG2 promoter in T47D cells and BeWo cells to sex hormone treatment. Mol Biol Rep. 2009 Sep;36(7):1889-96.
109	Differentiation of pancreatic acinar cells to hepatocytes requires an intermediate cell type. Gastroenterology. 2010 Jun;138(7):2519-30.
110	BCRP transports dipyridamole and is inhibited by calcium channel blockers. Pharm Res. 2005 Dec;22(12):2023-34.
111	Translation of in vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir. J Pharmacol Exp Ther. 2019 Jun 5. pii: jpet.119.256966.
112	Elucidation of the Impact of P-glycoprotein and Breast Cancer Resistance Protein on the Brain Distribution of Catechol-O-Methyltransferase Inhibitors. Drug Metab Dispos. 2017 Dec;45(12):1282-1291.
113	The metabolism and drug-drug interaction potential of the selective prostacyclin receptor agonist selexipag. Xenobiotica. 2018 Jul;48(7):704-719.
114	Cetuximab Prevents Methotrexate-Induced Cytotoxicity in Vitro through Epidermal Growth Factor Dependent Regulation of Renal Drug Transporters. Mol Pharm. 2017 Jun 5;14(6):2147-2157.
115	Toxic responses of swimming crab (Portunus trituberculatus) larvae exposed to environmentally realistic concentrations of oxytetracycline. Chemosphere. 2017 Apr;173:563-571.
116	Identification of Febuxostat as a New Strong ABCG2 Inhibitor: Potential Applications and Risks in Clinical Situations. Front Pharmacol. 2016 Dec 27;7:518.
117	In vivo and ex vivo regulation of breast cancer resistant protein (Bcrp) by peroxisome proliferator-activated receptor alpha (Ppar) at the blood-brain barrier. J Neurochem. 2015 Dec;135(6):1113-22.
118	Effect of venlafaxine and desvenlafaxine on drug efflux protein expression and biodistribution in vivo. J Pharm Sci. 2013 Oct;102(10):3838-43.
119	CD109 Promotes Drug Resistance in A2780 Ovarian Cancer Cells by Regulating the STAT3-NOTCH1 Signaling Axis. Int J Mol Sci. 2023 Jun 18;24(12):10306.; 2023 Jun 18;24(12):10306.
120	Nrf2-dependent and -independent induction of ABC transporters ABCC1, ABCC2, and ABCG2 in HepG2 cells under oxidative stress. J Exp Ther Oncol. 2007;6(4):335-48.
121	Aryl hydrocarbon receptor and aryl hydrocarbon nuclear translocator expression in human and rat placentas and transcription activity in human trophoblast cultures. Toxicol Sci. 2011 Sep;123(1):26-36.; 2011 Sep;123(1):26-36.
122	Correlation between Conjugated Bisphenol A Concentrations and Efflux Transporter Expression in Human Fetal Livers. Drug Metab Dispos. 2016 Jul;44(7):1061-5.; 2016 Jul;44(7):1061-5.
123	The AHR target gene scinderin activates the WNT pathway by facilitating the nuclear translocation of beta-catenin. J Cell Sci. 2022 Oct 15;135(20):jcs260028.; 2022 Oct 15;135(20):jcs260028.
124	Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2). Drug Metab Dispos. 2005 May;33(5):614-8.
125	Id-1 gene downregulation by sulindac sulfide and its upregulation during tumor development in gastric cancer. Int J Cancer. 2006 Mar 15;118(6):1356-63.
126	Classification of heavy-metal toxicity by human DNA microarray analysis. Environ Sci Technol. 2007 May 15;41(10):3769-74.
127	Cyclooxygenase inhibitors down regulate P-glycoprotein in human colorectal Caco-2 cell line. Pharm Res. 2008 Sep;25(9):1991-2001.
128	Activation of beta-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells. J Neurochem. 2008 Aug;106(4):1855-65.
129	ABCG2/BCRP decreases the transfer of a food-born chemical carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in perfused term human placenta. Toxicol Appl Pharmacol. 2008 Oct 15;232(2):210-7.
130	Induction of cells differentiation and ABC transporters expression by a myco-estrogen, zearalenone, in human choriocarcinoma cell line (BeWo). Toxicology. 2009 Sep 19;263(2-3):100-7.
131	Monoisoamyl dimercaptosuccinic acid abrogates arsenic-induced developmental toxicity in human embryonic stem cell-derived embryoid bodies: comparison with in vivo studies. Biochem Pharmacol. 2009 Nov 15;78(10):1340-9.
132	Identification of AhR-regulated genes involved in PAH-induced immunotoxicity using a highly-sensitive DNA chip, 3D-Gene Human Immunity and Metabolic Syndrome 9k. Toxicol In Vitro. 2010 Feb;24(1):85-91.
133	Modulation of stress genes expression profile by nitric oxide-releasing aspirin in Jurkat T leukemia cells. Biochem Pharmacol. 2010 Jun 15;79(12):1759-71.
134	Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition. PLoS One. 2011 Jan 31;6(1):e16530.
135	Oleic acid decreases BCRP mediated efflux of mitoxantrone in Caco-2 cell monolayers. Food Chem Toxicol. 2012 Oct;50(10):3635-45.
136	The effects of aflatoxin B1 on transporters and steroid metabolizing enzymes in JEG-3 cells. Toxicol Lett. 2013 Apr 26;218(3):200-6.
137	Improving cytocompatibility of Co28Cr6Mo by TiO2 coating: gene expression study in human endothelial cells. J R Soc Interface. 2013 Jul 3;10(86):20130428.
138	Endocrine disruptors differentially target ATP-binding cassette transporters in the blood-testis barrier and affect Leydig cell testosterone secretion in vitro. Toxicol Sci. 2013 Dec;136(2):382-91.
139	Comparative toxicogenomic responses of mercuric and methyl-mercury. BMC Genomics. 2013 Oct 11;14:698.
140	A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
141	CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. J Clin Invest. 2016 Feb;126(2):639-52.
142	The xenoestrogens, bisphenol A and para-nonylphenol, decrease the expression of the ABCG2 transporter protein in human term placental explant cultures. Mol Cell Endocrinol. 2016 Jul 5;429:41-9.
143	Selective GPR55 antagonism reduces chemoresistance in cancer cells. Pharmacol Res. 2016 Sep;111:757-766.
144	Whole genome mRNA transcriptomics analysis reveals different modes of action of the diarrheic shellfish poisons okadaic acid and dinophysis toxin-1 versus azaspiracid-1 in Caco-2 cells. Toxicol In Vitro. 2018 Feb;46:102-112.
145	Triclosan treatment decreased the antitumor effect of sorafenib on hepatocellular carcinoma cells. Onco Targets Ther. 2018 May 18;11:2945-2954.
146	Inhibition and stimulation of the human breast cancer resistance protein as in vitro predictor of drug-drug interactions of drugs of abuse. Arch Toxicol. 2018 Sep;92(9):2875-2884.
147	Anandamide down-regulates placental transporter expression through CB2 receptor-mediated inhibition of cAMP synthesis. Pharmacol Res. 2019 Mar;141:331-342.
148	Mechanistic investigations of the liver toxicity of the free fatty acid receptor 1 agonist fasiglifam (TAK875) and its primary metabolites. J Biochem Mol Toxicol. 2019 Aug;33(8):e22345.
149	Ginsenoside Rg3 attenuates the osimertinib resistance by reducing the stemness of non-small cell lung cancer cells. Environ Toxicol. 2020 Jun;35(6):643-651.
150	Comparison of long-term versus short-term effects of okadaic acid on the apoptotic status of human HepaRG cells. Chem Biol Interact. 2020 Feb 1;317:108937.
151	Prenatal ethanol exposure increases maternal bile acids through placental transport pathway. Toxicology. 2021 Jun 30;458:152848.
152	Concentration-dependent effects of chlorpyrifos oxon on peroxisome proliferator-activated receptor signaling in MCF-7 cells. Toxicol In Vitro. 2022 Feb;78:105268.
153	The mechanisms for lung cancer risk of PM2.5 : Induction of epithelial-mesenchymal transition and cancer stem cell properties in human non-small cell lung cancer cells. Environ Toxicol. 2017 Nov;32(11):2341-2351.
154	Assessment of a 72-hour repeated exposure to Swedish snus extract and total particulate matter from 3R4F cigarette smoke on gingival organotypic cultures. Food Chem Toxicol. 2019 Mar;125:252-270.
155	ABCG2-dependent dye exclusion activity and clonal potential in epithelial cells continuously growing for 1 month from limbal explants. Invest Ophthalmol Vis Sci. 2011 Jun 17;52(7):4330-7.
156	Interactions between Oroxylin A with the solute carrier transporters and ATP-binding cassette transporters: Drug transporters profile for this flavonoid. Chem Biol Interact. 2020 Jun 1;324:109097.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.

Detail Information of Exogenous Modulation

Visitor Map

Correspondence